Working… Menu
Trial record 38 of 266 for:    Pancreatic Cancer AND Resectable

A Pilot Study of IRE for Resectable Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03337997
Recruitment Status : Not yet recruiting
First Posted : November 9, 2017
Last Update Posted : April 30, 2019
Saskatchewan Health Research Foundation
Information provided by (Responsible Party):
Michael Moser, University of Saskatchewan

Brief Summary:

The operation to remove certain pancreatic cancers (Whipple procedure), even in 2017, remains one of the most complicated surgeries done in the abdomen. It carries a 50% chance of a complication, even in the world's largest pancreatic surgery centres.

Saskatchewan is one of only two centres in Canada to have a promising new technology called Irreversible Electroporation (IRE) (NanoKnife®) available to our patients for the ablation (destruction) of cancers. IRE is different from other ablation treatments, including heat and even radiation, in that with IRE no heat is generated and there is minimal, if any, damage to nearby blood vessels, bowel, and ducts. Thus far, IRE has only been used as a "last resort" in cases where the pancreatic cancer cannot be removed with surgery, yet many patients whose tumor could likely be removed with a 'Whipple' have expressed a preference to undergo IRE instead of the Whipple procedure.

Our main research questions are: In comparison to Whipple procedure, is IRE an effective treatment of pancreatic cancer, and are complications reduced? Is IRE cost-effective? Based on the cases we have done and published series of IRE for stage III pancreatic cancer, we believe that IRE will be effective and safe in treating lesser stage (I and II) tumors in our proposed study.

This will be a pilot study of 12-15 patients, and all recruited patients will receive the IRE treatment and then be followed for up to 5 years for quality of life, recurrence, survival, and cost.

Condition or disease Intervention/treatment Phase
Pancreatic Adenocarcinoma Resectable Procedure: Irreversible Electroporation Not Applicable

Detailed Description:
  • Subjects will receive a general anesthetic and will undergo a midline laparotomy and a careful inspection to ensure no distant metastases are obvious in the peritoneal cavity.
  • Ultrasound-guided IRE of the pancreatic mass will be performed by interventional radiologist Dr. Chris Wall as per the protocol of Martin et al [ ].
  • Subjects will be monitored for adverse events in the postoperative period until the time of discharge from the hospital, typically on the 5th or 6th day after the procedure.
  • Adjuvant chemotherapy is recommended following the procedure but it is not mandatory.
  • Patients will be assessed and offered single agent gemcitabine or combination of gemcitabine and capecitabine at the discretion of treating oncologists. It is recommended that patients begin treatment within 12 weeks after the procedure.
  • Specific drug reductions and management of will be made in accordance with the published recommendations for gemcitabine or gemcitabine plus capecitabine.
  • Patients will be scheduled for regular follow up and surveillance history and physical exam by the Hepatobiliary Surgeons Group.
  • The same surveillance protocol that is used after the Whipple procedure will be followed: bloodwork at 3, 6, 9, 12, 18, 24, 36, 48, and 60 months (complete blood count, electrolytes, creatinine, liver enzymes, Ca 19.9) and imaging (Chest Xray and CT abdomen at 3 months, followed by a PET scan at 6 months, CT scan at 9 and 12 months, then yearly CT or MRI).
  • For study purposes, each scan will be re-reviewed by the same two radiologists with a goal of arriving at a consensus in each case.
  • Two validated QOL questionnaires, the FACT-Hep, which is specific to hepatic and pancreatic diseases, and the more general FACT-G questionnaire will be administered preoperatively and at 3 and 12 months.
  • Each IRE case will be matched 2:1 with patients undergoing the Whipple Procedure around the same time (within 12 months of each other) for non-locally advanced pancreatic cancer, matched by age +/- 5 years, gender, tumor size +/- 0.5 cm, and preoperative chemotherapy.
  • Survival curves will be analyzed using the Kaplan-Meier method, and differences between groups will be assessed using log-rank test.
  • Student's T test and the Mann-Whitney U test will be used for other comparisons between the two groups and p<0.05 will be taken to be significant. SPSS version 24 will be used for statistical analyses (SPSS Inc, Chicago, IL).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Patients with biopsy-proven adenocarcinoma of the head of the pancreas deemed to be resectable by a multi-disciplinary team will be invited to participate.
Masking: None (Open Label)
Masking Description: CT scans and PET scans will be read by two radiologists and concensus obtained. The two radiologists will be unaware of prior chemo, patient age, original tumor size.
Primary Purpose: Treatment
Official Title: A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas
Estimated Study Start Date : October 1, 2019
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : January 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Study group
All patients in this pilot study are in the same group. All receive Irreversible Electroporation.
Procedure: Irreversible Electroporation
Open Irreversible Electroporation by ultrasound guidance for tumors under 3 cm in diameter. Goal is to obtain an Amp rise of 12 or more
Other Names:
  • NanoKnife
  • IRE

Primary Outcome Measures :
  1. Disease Free Survival [ Time Frame: 5 years ]
    Disease Free Survival

  2. Complications [ Time Frame: 3 months ]
    recorded and classified

Secondary Outcome Measures :
  1. Length of Stay [ Time Frame: 1 month ]

  2. Quality of Life (Functional Assessment of Cancer Therapy- for Hepatobiliary and Pancreatic Cancers) questionnaire [ Time Frame: preoperatively, 3 months, 12 months ]
    This is a validated measure of quality of life in patients who have hepato-pancreatico-biliary cancers, and includes 45 items that the patient scores on a scale of 0-4, with 4 being very symptomatic and 0 being asymptomatic. Higher scores imply a worse quality of life.

  3. Time to recurrence [ Time Frame: 5 years ]

  4. Overall Survival [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy-proven pancreatic adenocarcinoma of the head of the pancreas.
  • Age 18 to 75.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Pregnancy
  • Subjects who are medically unfit to receive a general anesthetic.
  • Patients with cardiac arrhythmia other than rate controlled atrial fibrillation.
  • Tumors greater than 3 cm.
  • Unresectable or locally advanced pancreatic cancer.
  • Patients with a high suspicion for lymph node metastasis or peripancreatic pathologic (> 1 cm) lymph nodes on imaging.
  • Metastatic pancreatic carcinoma, including unexpected peritoneal or liver metastases discovered at the time of laparotomy for planned IRE.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03337997

Layout table for location contacts
Contact: Michael A Moser, MD 306-655-5319

Layout table for location information
Canada, Saskatchewan
University of Saskatchewan Not yet recruiting
Saskatoon, Saskatchewan, Canada, S7N 0W8
Contact: Michael A Moser, MD    306-655-5319   
Contact: Shahid Ahmed, MD    306-655-1000   
Sponsors and Collaborators
University of Saskatchewan
Saskatchewan Health Research Foundation

Layout table for additonal information
Responsible Party: Michael Moser, Principal Investigator, University of Saskatchewan Identifier: NCT03337997     History of Changes
Other Study ID Numbers: IRE002
First Posted: November 9, 2017    Key Record Dates
Last Update Posted: April 30, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Michael Moser, University of Saskatchewan:
Irreversible Electroporation
Pancreatic Adenocarcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type